Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$494K Sell
1,061
-126
-11% -$53K 0.17% 54
2026
Q1
$448K Sell
1,187
-42
-3% -$18K 0.16% 55
2025
Q4
$526K Sell
1,229
-93
-7% -$40.5K 0.19% 48
2025
Q3
$592K Buy
1,322
+256
+24% +$116K 0.21% 48
2025
Q2
$519K Buy
1,066
+17
+2% +$9.69K 0.19% 50
2025
Q1
$646K Sell
1,049
-346
-25% -$197K 0.25% 39
2024
Q4
$739K Sell
1,395
-111
-7% -$62.6K 0.26% 40
2024
Q3
$905K Buy
1,506
+493
+49% +$279K 0.38% 34
2024
Q2
$550K Buy
+1,013
New +$580K 0.24% 53

Other funds holding CHE

Clarus Group's CHE Position: Q2 2026 in Review

Clarus Group reduced its Chemed (CHE) stake by 11% in Q2 2026, selling an estimated $53K and leaving 1,061 shares worth $494K. The position accounts for 0.17% of the portfolio, ranked #54.

Clarus Group first reported a position in CHE in Q2 2024 and has held it in 9 quarters since. The position peaked at $905K in Q3 2024. 532 funds tracked by Wall St. Rank hold CHE as of Q2 2026.

  • Clarus Group held 1,061 shares of Chemed worth $494K as of Q2 2026.
  • Clarus Group sold 126 Chemed shares in Q2 2026, an estimated $53K.
  • Chemed made up 0.17% of Clarus Group's portfolio in Q2 2026, its #54 holding.
  • Clarus Group first reported a position in Chemed in Q2 2024 and has held it in 9 quarters since.
  • Clarus Group's Chemed position peaked at $905K in Q3 2024.
  • 532 funds tracked by Wall St. Rank held Chemed as of Q2 2026.

Based on Clarus Group's 13F filing for Q2 2026, filed 24 Jul 2026.